Medbio expands implant molding capabilities


Medbio has announced that it has launched another dedicated implant molding cell to help expand the company’s injection molding offerings.

“We’re excited about our growth and the expanded capabilities in implantable components,” said John Woodhouse, director of sales and marketing for Medbio. “We’ve increased our capacity to meet the growing needs of our customers and we are better positioned to support the fast growing implant sector in the medical device industry.”

The expansion adds two 55-ton electric presses and Arbor’s micro molding modules to the new implant molding cell. The presses are also in an ISO class 7 cleanroom. Top-performing operators have been assigned to the new cell and are expected to receive specialized, ongoing training.

Medbio attributes continuous growth in its implantable component manufacturing for neurology and orthopedic OEMs to its newest molding capacity expansion.

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Speak Your Mind